Cybin to Participate in the 2022 Maxim Group Virtual Growth Conference on March 28-30, 2022
16 Marzo 2022 - 2:40PM
InvestorsHub NewsWire
TORONTO, Canada -- March 16, 2022 -- InvestorsHub
NewsWire -- Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ("Cybin"
or the "Company"), a biopharmaceutical company
focused on progressing "Psychedelics to Therapeutics™" is pleased
to announce that Doug Drysdale, Cybin's Chief Executive Officer,
will present at the 2022 Virtual Growth Conference, presented by
Maxim Group LLC and hosted by M-Vest, taking place March
28th - 30th from 9:00 a.m. - 5:00
p.m. ET.
Mr. Drysdale's presentation will be available on demand
beginning at 9:00 a.m. ET on Monday, March 28th. To
attend, please register
here to access the conference. To listen to the
presentation, please click
here to access the webcast. The archived webcast will also
be available on the Company's investor relations website on
the Events &
Presentations page.
About Cybin
Cybin is a leading ethical biopharmaceutical company, working with
a network of world-class partners and internationally recognized
scientists, on a mission to create safe and effective therapeutics
for patients to address a multitude of mental health issues.
Headquartered in Canada and founded in 2019, Cybin is operational
in Canada, the United States, United Kingdom and Ireland. The
Company is focused on progressing Psychedelics to Therapeutics by
engineering proprietary drug discovery platforms, innovative drug
delivery systems, novel formulation approaches and treatment
regimens for mental health disorders.
Contacts
Investor & Media:
Leah Gibson
Vice President, Investor Relations
Cybin Inc.
leah@cybin.com
Grafico Azioni Cybin (AMEX:CYBN)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Cybin (AMEX:CYBN)
Storico
Da Giu 2023 a Giu 2024